FDA 483 - Novartis Gene Therapies, Inc. - June 16, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Novartis Gene Therapies, Inc. in Libertyville, IL, received a Form 483 with five observations during an FDA inspection of its gene therapy manufacturing facility. The inspection revealed significant deficiencies in laboratory controls, including inadequate procedures for OOS/OOT investigations, trending invalid analytical tests, and identifying Out of Expectation results. Additionally, the firm failed to retain reserve samples for drug products, lacked appropriate specifications for component quality, and had incomplete laboratory records.
ID · 9b49b78c-7eb5-4d4b-8c48-7f5739a303b9